Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.